<DOC>
	<DOCNO>NCT02672449</DOCNO>
	<brief_summary>The aim research project test feasibility safety new treatment schedule high risk prostate cancer allow administration high dos prostate tumor mixed beam approach carbon ion boost follow pelvic IMRT .</brief_summary>
	<brief_title>Carbon Ions Boost Followed Pelvic Photon Radiotherapy High Risk Prostate Cancer</brief_title>
	<detailed_description>The present research project aim improve current treatment high risk prostate cancer , evaluate safety feasibility new RT scheme carbon ion boost follow pelvic photon RT . A total 65 consecutive patient enrol prospective phase II trial . The patient enrol either Centro Nazionale di Adroterapia Oncologica ( CNAO ) , Pavia , Italy , Division Radiation Oncology European Institute Oncology ( IEO ) , Milan , Italy , Fondazione IRCCS Istituto Nazionale Tumori ( INT ) , Milan , Italy . The treatment include boost phase whole prostate carbon ion perform CNAO follow pelvic photon IMRT perform conventional fractionation 1.8 Gy per fraction 45 Gy pelvic lymph node , prostate seminal vesicle . All patient data collect common database accessible 3 Institutions . At CNAO , carbon ion beam available patient treatment since 2011 . In comparison Japanese Center NIRS , facility relies active beam delivery use rasterscan technique , offer physical advantage well spar normal tissue entrance channel , also enable biologic plan optimization . The facility equipment Carbon Ion Treatment Center Heidelberg , Germany . At CNAO , 3D - 4D patient target localization verify fraction integrate orthogonal X-ray image 3D real time optical tracking system . At IEO INT , IMRT phase perform treatment modality : volumetric-IMRT RapidArc Varian Trilogy ( IEO ) Varian DHX ( INT ) linac , Varian Medical Systems , Palo Alto , CA , USA , treatment base isocentric beam delivery , pre-treatment image guidance patient alignment via cone beam CT portal imaging . In phantom , quality assurance ( QA ) treatment perform patient RT , order verify consistency calculate deliver dose .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate , highrisk category accord NCCN version 2013 ( T3a and/or PSA &gt; 20 ng/ml and/or Gleason score 810 ) cN0 cM0 Good performance status ( ECOG &lt; 2 ) No previous pelvic RT No previous prostatectomy No concomitant bowel inflammatory disease serious comorbidities Good urinary flow ( peak flow &gt; 10 ml/s ) No previous invasive cancer ( within 5 year PCa diagnosis ) apart nonmelanoma skin malignancy . Exclusion criterion Pelvic lymph node metastasis ( N1 ) Distant metastasis ( M1 ) Urinary obstructive symptom ( IPSS &gt; 20 ) Previous pelvic radiotherapy Severe systemic disorder Concomitant disorder include : chronic urinary intestinal inflammatory condition ( example , ulcerous rectocolitis , Crohn disease ) , anticoagulant treatment ( warfarin , heparin ) Previous malignancy except skin nonmelanoma cancer 3year disease free interval previous malignancy like situ cervix cancer non muscle invasive bladder cancer Non conformity radiotherapy dose distribution compare dose constraint Psychiatric disorder condition make unreliable informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Carbon ion</keyword>
	<keyword>Radiobiology</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>